Description
Jintropin Vials
Composition and Product Form
Jintropin main active ingredient: somatropin.
Inactive ingredients: mannitol, glycine, sodium dihydrogen phosphate, sodium chloride.
It is produced in the form of lyophilized powder for injections, in vials at a dosage of 10 IU (3.33 mg) of somatropin.
Pharmacological Properties
This medication is part of the group of medications based on hormones secreted by the lobes of the pituitary gland – a gland discharging iron internal secretion used at the base of the skull.
The medication of the human hormone somatropin (recombinant chondrotropic hormone) is a protein secreted by the bacterial cells of E. coli. Among the genes of these bacteria, there is one containing the encoded growth rate of the organism.
In addition, the somatropin hormone affects both the rate at which a person grows and the metabolism, increase of glucose levels in the blood, body anatomy, and homeostasis. It mainly affects the growth of the long bones.
It is most effective when administered through injection, reaching its maximum result within 4 hours after use.
Use in Sports
Jintropin can make intensive training more effective and help create the perfect body contour. Chondrotropic hormone is a somatotropin medication that aids in building muscle in a short time and quickly burning body fat.
What JINTROPIN is Capable Of
- Enhancing the compaction of bone tissue, making it more flexible.
- Preventing muscle stretching during exercise.
- Improving metabolism, allowing you to burn calories.
- Preventing the accumulation of body fat.
- Helping to cure acute joint and ligament diseases.
- Promoting nail and hair regeneration with regular use.
Contraindications
This medication is contraindicated for patients with severe hypersensitivity (allergy) to the main or any of the inactive elements. It is also contraindicated in cases of epiphysis closure (cessation of bone growth), oncological diseases, and for children with chronic kidney diseases before kidney transplantation. Use with caution in cases of diabetes mellitus (hypoglycemic attacks are possible), hypothyroidism, increased intracranial pressure, and intracranial hypertension.
Method of Use and Dosage
The medication is administered through injection (subcutaneously and intramuscularly), under the constant supervision of an experienced physician with expertise in diagnosing and treating patients with chondrotropic hormone deficiency.
The recommended weekly dosage for chondrotropic hormone deficiency ranges from 0.6-0.7 IU/kg of body weight to 1.0 IU/kg of body weight. The dosage is divided into 6 – 7 equal parts and is taken subcutaneously or intramuscularly in the evening. In case of persistent edema or severe paresthesia, the dosage of the medication is reduced to avoid the development of tunnel syndrome. To prevent lipoatrophy, the injection site should be changed.
Jintropin Overdosage
Overdosage can cause a sharp decrease in insulin levels in the blood (hypoglycemia phenomenon). Subsequently, blood sugar levels rise sharply and hyperglycemia can develop. Chronic overdosage can lead to gigantism or acromegaly. Other phenomena related to excessive chondrotropic hormone dosage can also occur. In case of overdosage, treat the symptoms.
Side Effects
The medication is usually well tolerated. Possible side effects include:
- Increased hypersensitivity
- Itching and redness at the injection site
- Hypothyroidism
In some cases, if the complex chondrotropic hormone gene stimulates slight growth, treatment with somatropin can lead to the production of antibodies that inhibit the growth process. In such cases, epiphysiolysis can occur, accompanied by damage to the hip joint. A child with unexplained lameness should be examined.
Storage Terms and Conditions
The expiration date is 3 years from the production date specified on the package. The recommended temperature range for storage is 2-8°C.
A Randomized Controlled Phase 3 Study on the Efficacy and Safety of Recombinant Human Growth Hormone in Children With Idiopathic Short Stature
Reviews
There are no reviews yet.